GLP-1 &
Metabolic Response
The genetics behind your response to Ozempic, Wegovy, and Mounjaro. GLP1R, GIPR, and TCF7L2 variant profiling against the largest pharmacogenomic RCTs of semaglutide and tirzepatide to date.
⚠ Research Use Only. Not FDA-cleared or approved. Not intended to diagnose, treat, cure, or prevent any disease. Always discuss findings with a licensed healthcare provider.
See a fully rendered example — real RSIDs, peer-reviewed citations, and clinical action guidance — before you commit.
RSIDs analyzed in this panel
Representative variants. Full report includes all associated loci with genotyped values, effect sizes, and clinical interpretation.
Supporting literature
Nature 2026 GWAS (n=27,885) — first robust predictors of GLP-1 RA weight-loss efficacy and nausea/vomiting risk; GIPR rs1800437 tirzepatide-specific signal. Dawed et al. Lancet Diabetes & Endocrinology 2023 (DOI:10.1016/S2213-8587(22)00340-0) · n=4,571 across 5 RCTs · rs6923761 Gly168Ser p=6.0×10⁻⁵. Meidyana et al. PMC 2025 — semaglutide 2.4mg cohort n=112. PharmGKB GLP1R/GIPR annotation 2024.
Why this panel exists now
GLP-1 receptor agonists are the fastest-growing drug class in modern medicine. Individual response varies dramatically — some patients lose 20%+ body weight at therapeutic dose; others see minimal effect. Genetics is a significant and largely unexplored reason why. This panel is among the first consumer-accessible pharmacogenomic reports specifically built for the GLP-1 era.
What this report can and cannot tell you
This report tells you whether you carry GLP1R variants associated with altered receptor binding affinity and clinical response in large RCTs. It cannot predict precisely how much weight you will lose — non-genetic factors (gut absorption, diet, adherence, dose titration) are equally important. It is a starting point for a pharmacogenomics-informed conversation with your prescribing physician. RUO — not a prescription recommendation.
This report is for Research Use Only and is not FDA-cleared, FDA-approved, or CE-IVD certified. Polygenic risk scores and pharmacogenomic findings reflect statistical associations from published peer-reviewed GWAS studies. Results are not diagnostic and do not constitute medical advice. Always consult a licensed physician, genetic counselor, or pharmacist before acting on any finding. © 2026 AuraGen Wellness · auragenwellness.com
- ✓GLP1R rs6923761 (Gly168Ser) — receptor binding affinity for all GLP-1 RAs
- ✓GLP1R rs10305420 (Pro7Leu) — secondary GLP1R response modifier
- ✓GIPR rs1800437 (Glu354Gln) — tirzepatide-specific nausea & vomiting risk (Nature 2026 GWAS)
- ✓TCF7L2 rs7903146 — indirect GLP-1 sensitizer and T2D risk locus
- ✓CYP3A4*22 rs35599367 — drug metabolism speed modifier
- ✓Powered by Nature 2026 GWAS (n=27,885) + Lancet Diabetes & Endocrinology 2023 (n=4,571)
⚠ Research Use Only · Not FDA cleared